Arcotatug tavatecan clinical trials
Also written IBI343.
How each study uses arcotatug tavatecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the arcotatug tavatecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 5
Innovent Biologics (Suzhou) Co. Ltd. (5) · Zhejiang University (2) · Harbin Medical University (1) · Ruijin Hospital (1) · Zhejiang Cancer Hospital (1)
Often tested with
Tested in the same studies.
Sintilimab (2) · Gemcitabine (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Oxaliplatin (1) · Tegafur (1) · Gimeracil (1) · Oxonic Acid (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 2 in phase 3
Studies that test arcotatug tavatecan, phase 3 first.
- Dec 2026A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)Phase 3 · Innovent Biologics (Suzhou) Co. Ltd.
- Jun 2027A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)Phase 3 · Innovent Biologics (Suzhou) Co. Ltd.
- Jan 2027IBI343 Combined With Chemotherapy in Advanced Pancreatic CancerPhase 2 · Zhejiang University
- Jun 2027IBI343 Combined With Chemotherapy in Advanced Pancreatic CancerPhase 1/2 · Zhejiang Cancer Hospital
- Jun 2027A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsPhase 1 · Innovent Biologics (Suzhou) Co. Ltd.
- Jul 2027IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric CancerPhase 1/2 · Ruijin Hospital
Studies
Open first, then newest update. How each study uses arcotatug tavatecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)RecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07066098Written as IBI343
- IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric CancerRecruitingPhase 1/2Ruijin HospitalNCT07025889Written as IBI343
- IBI343 Combined With Chemotherapy in Advanced Pancreatic CancerRecruitingPhase 1/2Zhejiang Cancer HospitalNCT07692750Written as IBI343+ capecitabine
- IBI343 in Combination Therapy for Advanced Malignant Solid TumorsRecruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07483554Written as IBI343,Gemcitabine, Albumin-bound Paclitaxel
- IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07483567Written as IBI343,sintilimab,oxaliplatin,S-1
- A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05458219Written as IBI343
- IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic CancerNot yet recruitingPhase 2Zhejiang UniversityNCT07415525Written as IBI343
- IBI343 Combined With Chemotherapy in Advanced Pancreatic CancerRecruitingPhase 2Zhejiang UniversityNCT06770439Written as IBI343
- Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Harbin Medical UniversityNCT06321913Written as IBI343 combined with IBI308
- A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)Active, not recruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT06238843Written as IBI343
Codes
What other systems call arcotatug tavatecan · ClinicalTrials.gg INT018262
- UNII (FDA) VNF8V7Q4RSARCOTATUG TAVATECANOne source FDA
- NCI Thesaurus C189808Arcotatug TavatecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VNF8V7Q4RS | ARCOTATUG TAVATECAN | One source FDA |
| NCI Thesaurus | C189808 | Arcotatug Tavatecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.